|
|
|
|
|
|
|
Highlights from the 2025 European Society of Medical Oncology Annual Meeting |
|
|
|
| Patient Reported Outcomes from AMPLITUDE, a Trial of Niraparib and Abiraterone Acetate plus Prednisone in mHSPC with Homologous Recombination Repair Mutations |
| Dana Rathkopf, MD |
| In the AMPLITUDE trial, adding niraparib to abiraterone acetate and prednisone in HRR-mutated mHSPC significantly improved radiographic progression-free survival and time to symptomatic progression without compromising quality of life. Patient-reported outcomes showed only a mild, transient decline early in treatment, with overall health-related quality of life maintained throughout therapy. Most patients reported being minimally bothered by side effects, confirming the regimen’s favorable tolerability. |
|
|
|
|
|
| Effects of Prostate Radiotherapy on Synchronous, Metastatic, Hormone-Sensitive Prostate Cancer (mHSPC): STOPCAP Meta-Analysis of Individual Participant Data |
| Peter Godolphin, MSc, PhD |
| The STOPCAP individual patient data meta-analysis found that adding prostate radiotherapy (RT) to standard care modestly improved overall and progression-free survival in men with de novo metastatic hormone-sensitive prostate cancer. The benefit was most pronounced in patients with low-volume disease or fewer than five bone metastases, with about a 5–8% absolute improvement in 5-year survival. The effect of RT was consistent regardless of concurrent docetaxel use. |
|
|
|
|
|
| 3-Weekly Docetaxel 75 mg/m2 vs 2-Weekly Docetaxel 50 mg/m2 in Combination with Darolutamide + ADT in Pts with mHSPC – Results from the Randomised Phase 3 ARASAFE Trial |
| Marc-Oliver Grimm, MD |
| The ARASAFE phase 3 trial found that biweekly docetaxel 50 mg/m² combined with darolutamide and ADT significantly reduced grade 3–5 adverse events and grade 3–4 neutropenia or death compared to the standard 3-weekly 75 mg/m² regimen, despite a higher cumulative docetaxel dose. Hematologic toxicities were notably lower with the biweekly schedule, while biochemical efficacy, measured by PSA suppression, was maintained. |
|
|
|
|
|
| mHSPC in 2025: More, Less, or Smarter?
|
| Yüksel Ürün, MD
|
| Yüksel Ürün highlighted that the management of metastatic hormone-sensitive prostate cancer (mHSPC) is evolving from ADT alone to tailored doublet and triplet therapies, balancing efficacy with tolerability. He emphasized that AMPLITUDE shows biomarker-driven intensification can improve outcomes without compromising quality of life, STOPCAP demonstrates local prostate radiotherapy benefits progression-free survival in low-volume disease, and ARASAFE indicates that biweekly docetaxel reduces toxicity while maintaining treatment intensity.
|
|
|
|
|
|
|
|
|
|
|
| First Interim Efficacy Analysis of the Phase 1/2 PETRANHA Trial of Saruparib + Androgen Receptor Pathway Inhibitors (ARPI) in Patients (Pts) with Metastatic Prostate Cancer |
| Arun Azad, MBBS, PhD, FRACP |
| Azad presented interim results from the Phase 1/2 PETRANHA trial showing that saruparib, a next-generation PARP1-selective inhibitor, combined with androgen receptor pathway inhibitors (ARPIs) was well tolerated in patients with metastatic prostate cancer, with manageable Grade ≥3 adverse events and no cases of myelodysplastic syndrome. |
|
|
|
|
|
| Translational Analyses of T-Cell Phenotypes and Their Association with Clinical Efficacy in the First-in-Human Trial of JNJ-78278343 (Pasritamig) in Metastatic Castration-Resistant Prostate Cancer |
| Karen Autio, MD, MSc |
| Karen Autio presented translational analyses from the first-in-human trial of pasritamig in mCRPC, showing that extending dosing intervals from every 1–3 weeks to every 6 weeks improved clinical responses by preserving a pool of progenitor CD8⁺ T cells and reducing T-cell exhaustion and activation-induced cell death. PSA50 responses were higher with the Q6W schedule, and biomarker analyses confirmed that this regimen maintains reprogrammable, stem-like T cells capable of anti-tumor effector function. |
|
|
|
|
|
| Single-Dose Carboplatin and Involved-Node Radiotherapy for Seminoma Stage IIA/B: Long-Term Follow-up from the International Multicenter Phase II Trial SAKK 01/10 |
| Alexandros Papachristofilou, MD |
| The SAKK 01/10 trial demonstrated that single-dose carboplatin followed by involved-node radiotherapy provides durable long-term control for stage IIA/B seminoma, with a 10-year progression-free survival of 92.8% and 100% seminoma-specific survival. The regimen showed minimal acute and late toxicity, with no treatment-related secondary malignancies observed, supporting its incorporation as a safe and effective treatment option. |
|
|
|
|
|
| A Phase 2 Study of Avelumab in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-Based Chemotherapy or Progressed on or after Platinum-Based Chemotherapy (ALPACA)
|
| Srikala S. Sridhar, MD, MSc, FRCPC
|
| The ALPACA phase 2 trial demonstrated that avelumab is safe and moderately active in patients with advanced penile cancer refractory to or unfit for platinum-based chemotherapy, achieving a 17% objective response rate with durable responses in a heavily pretreated cohort. Despite manageable toxicity, overall progression-free and overall survival remained poor, highlighting the urgent need for biomarkers to identify responders and for exploring earlier or combination treatment strategies in this rare malignancy.
|
|
|
|
|
|
| Long-Term SAKK 01/10 Seminoma Outcomes and the ALPACA Avelumab Study
|
| Gunhild von Amsberg, MD
|
| Gunhild von Amsberg highlighted that clinical trials in rare GU cancers face major logistical challenges, with ALPACA showing that avelumab has modest efficacy in heavily pretreated metastatic penile cancer, though responders experienced durable benefit, emphasizing the need for biomarkers and careful patient selection. In contrast, long-term results from the SAKK 01/10 seminoma trial demonstrated that single-dose carboplatin plus involved-node radiotherapy provides excellent 10-year progression-free and disease-specific survival with minimal toxicity, supporting de-escalation strategies. |
|
|
|
|
|
|
|
|
|
|
